GSK

What an inspiring few days at #ATS2026! We're leaving feeling incredibly energised by the collective drive to advance respiratory medicine, and the continued focus on what truly matters for patients. For patients living with respiratory conditions like severe asthma and COPD, there is a clear need for therapies that move beyond symptom relief. At ATS, we gained invaluable insights reinforcing our commitment to stabilising and stopping disease progression. This work is crucial for preventing devastating patient events like exacerbations and hospitalisations and easing the burden on healthcare systems.

#RefractoryChronicCough (#RCC) is a debilitating disease that may be associated with hypersensitive nerves (neuronal hypersensitivity) and can cause patients to cough more than 400 times a day. Patients with RCC report a wide range of physical and psychosocial complications and face lengthy pathways to diagnosis as they search for answers. At #ATS2026, we're committed to changing that by sharing new research on refractory chronic cough to help advance disease management and support patients like Mary Ellen.

As part of our ambition for the future of respiratory health, we're looking at long-acting therapies, and the role they could play in advancing disease management. At #ATS2026, new insights look at patient preference for long-acting options and how these could improve adherence, outcomes and help overcome real-world treatment hurdles.

Uncontrolled, severe asthma places a heavy burden on patients, disrupting daily life and leading to unpredictable exacerbations, or attacks, emergency visits, and hospitalisations. That’s why we’re here at #ATS2026, innovating for the future of respiratory health – so patients like Michael can experience lasting relief, and don’t have to think about their every breath.

#News for #Investors and #Media: Today, we are announcing that one of our vaccines has been approved for an expanded population by the Japanese Ministry of Health, Labour and Welfare (MHLW). Learn more: https://gsk.to/4dx3sgg

We’re energised to be at #ATS2026 and inspired to push further in our mission to redefine respiratory care for better patient outcomes. People living with asthma and COPD deserve more than symptom relief – they deserve treatments that protect against exacerbations, prevent lung damage and slow disease progression. We remain committed to working alongside healthcare professionals and researchers to improve outcomes for the millions of people living with chronic respiratory conditions.

Behind every COPD exacerbation statistic is a moment like this: frightening, disorienting, disrupting. But some of these moments may be preventable. COPD exacerbations, or attacks, can cause irreversible lung damage, and place a heavy burden on those living with the disease. The impact also extends beyond the patient, increasing pressure on carers, the workforce and healthcare systems, with hospital admissions costing 2-3 times more than those unrelated to COPD. COPD is a leading cause of preventable hospitalisations. It’s time to change that through earlier, proactive COPD care to help reduce exacerbations.

At #ATS2026, we're sharing findings from 33 research projects across our portfolio of inhaled therapies and biologics – reflecting our ambitious treatment goals, moving beyond symptom control to transform outcomes for people living with chronic respiratory diseases like asthma and chronic obstructive pulmonary disease (COPD). Our innovation is driving new treatment approaches including long-acting therapies, which aim to redefine care and alleviate the significant burden on patients and health systems worldwide. We believe advancing research is one of the most meaningful investments we can make for a healthier future.

Today, on #WorldLupusDay, we're joining the global community to #MakeLupusVisible. This complex autoimmune disease silently impacts nearly 5 million people worldwide. For people like Monique who live with lupus, early, targeted intervention can make a positive impact, helping to manage disease progression and reduce the risk of organ damage. At GSK, we're committed to understanding the immune system's complexities and advancing the science in lupus care to help people like Monique improve their quality of life and thrive. Join us in raising awareness. Wear purple – the colour for lupus awareness – spread the word, and make a difference for people living with lupus.

On #WorldOvarianCancerDay, we’re joining the global community to raise awareness of the unique challenges faced by people living with ovarian cancer. Through our ‘Your Cancer Is Our Challenge’ programme, we've learned that patients often feel uncertain about what to expect during treatment, and many want to know more about how different types of tests could help inform their treatment plan. Watch Dr Amina Ahmed, a leading gynaecologic oncologist, as she shares her insights into the crucial role of genetic testing in treatment planning. #WOCD2026